RPID (Rapid Micro Biosystems) Moat Score: 4/10 (As of Jul. 01, 2026)


RPID Rapid Micro Biosystems Inc RPID
60 GF Score
Price $1.71
GF Value $1.88
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Rapid Micro Biosystems Moat Score?

Rapid Micro Biosystems RPID -1.16% 60 Moat Score is 4 as of Jul. 01, 2026. GuruFocus rates RPID with a GF Score™ of 60/100 and a GF Value™ of $1.88 (Fairly Valued). The stock has 4 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Rapid Micro Biosystems ranks better than 83.33% on this metric.

Rapid Micro Biosystems has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Rapid Micro Biosystems has Narrow Moat: Rapid Micro Biosystems Inc has a modest moat due to its proprietary technology and innovation in microbiology testing. However, it faces competitive pressures that limit its market share and pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Rapid Micro Biosystems might have Narrow Moat - Discernible but modest moat.

Rapid Micro Biosystems  (NAS:RPID) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Rapid Micro Biosystems Moat Score Related Terms

RPID vs OM, NNOX, STIM: Moat Score Comparison

For the Medical Devices subindustry, Rapid Micro Biosystems's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Micro Biosystems Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's Moat Score distribution charts can be found below:

* The bar in red indicates where Rapid Micro Biosystems's Moat Score falls into.


RPID
60GF Score
Rapid Micro Biosystems Inc RPID
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Rapid Micro Biosystems (RPID) has a Moat Score of 4 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Rapid Micro Biosystems ranks #141 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 16.7%.
Is Rapid Micro Biosystems' Moat Score too high?
Rapid Micro Biosystems' current Moat Score is 4. Based on the distribution chart, Rapid Micro Biosystems ranks #141 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Rapid Micro Biosystems has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rapid Micro Biosystems' Moat Score compare to OM and NNOX?
According to the Medical Devices & Instruments industry distribution chart, Rapid Micro Biosystems ranks #141 out of 846 companies for Moat Score. This places Rapid Micro Biosystems in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Rapid Micro Biosystems's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Micro Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Rapid Micro Biosystems (RPID) is currently considered Fairly Valued. The stock's GF Value™ is $1.88, compared to a current price of $1.71 — trading 9% below its estimated fair value. The current Moat Score is 4. Rapid Micro Biosystems' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Rapid Micro Biosystems (RPID), the current Moat Score is 4 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rapid Micro Biosystems (RPID) Overvalued in 2026?

Based on GuruFocus' analysis, Rapid Micro Biosystems stock appears to be undervalued. The current stock price of $1.71 is trading 9% below its estimated GF Value™ of $1.88. GuruFocus considers Rapid Micro Biosystems to be Fairly Valued.

Key valuation signals for RPID:

  • Moat Score: 4
  • GF Value™: $1.88 vs. price of $1.71 (9% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the RPID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rapid Micro Biosystems Business Description

Address 25 Hartwell Avenue, Lexington, MA, USA, 02421
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
60GF Score

Get the complete analysis for RPID

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price
$1.88
GF Value